Pleural mesothelioma
MONDO:0003308A neoplasm that arises from the mesothelial cells of the pleura. The primary cause is exposure to asbestos. The major histologic variants are the epithelioid malignant mesothelioma, desmoplastic malignant mesothelioma, and sarcomatoid malignant mesothelioma. Patients present with persistent cough and shortness of breath.
Also known as: mesothelioma of pleura, mesothelioma of the pleura, pleura mesothelioma, pleural mesothelioma, pleural mesothelioma (disease), benign pleural mesothelioma, pleural mesothelioma (disease), benign
1517 clinical trials for this condition and its sub-types, 28 tagged with Pleural mesothelioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pleural mesothelioma
-
Malignant pleural mesothelioma 71 trials · 75 incl. sub-types
2 sub-types
- Pleural epithelioid mesothelioma 8 trials
- Pleural sarcomatoid mesothelioma 2 trials
-
Pleural adenomatoid tumor 0 trials
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase 1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
Disease control Recruiting nowThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to stall rare lung cancer
Disease control Recruiting nowThis study tests whether adding an experimental immunotherapy (fianlimab) to standard treatment (cemiplimab plus chemotherapy) can better control pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 126 people who have not yet been treated will receive one…
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for mesothelioma: drug targets cancer from two angles
Disease control Recruiting nowThis phase 2 trial tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer has returned after immunotherapy and chemotherapy. The drug works by blocking blood vessel growth and boosting the immune system to fight cancer. The main goal is to see if the …
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising drug targets tough mesothelioma in early trial
Disease control Recruiting nowThis study tests a drug called sacituzumab govitecan in 33 adults with mesothelioma that has come back or spread. Participants receive the drug until their disease worsens or side effects become too severe. The main goal is to see if the drug can shrink tumors and help control th…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill-and-immunotherapy cocktail takes on advanced tumors
Disease control Recruiting nowThis study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…
Phase 1/2 • Sponsor: 7 Hills Pharma, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New triple-threat approach targets deadly mesothelioma in early trial
Disease control Recruiting nowThis early-phase trial tests whether adding the immunotherapy drug pembrolizumab and a special imaging technique during surgery can improve treatment for malignant pleural mesothelioma, a rare and aggressive lung cancer. About 20 adults with measurable disease will receive the co…
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy targets hard-to-treat mesothelioma
Disease control Recruiting nowThis study tests a new two-step treatment for people with malignant pleural mesothelioma, a rare and serious cancer of the lung lining. First, doctors use a special light therapy during a scope procedure to kill cancer cells. Then, patients receive an immunotherapy drug called ni…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cancer diagnostic tool could change how doctors choose treatments
Diagnosis Recruiting nowThis study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…
Sponsor: Azienda Ospedaliero-Universitaria di Parma • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Surgery for 'unremovable' mesothelioma? new study tests symptom relief
Symptom relief Recruiting nowThis study looks at whether a surgery called partial pleurectomy (removing part of the lung lining) can help with symptoms and quality of life in people with advanced pleural mesothelioma that cannot be fully removed. About 30 participants will have the surgery and fill out sympt…
Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Mapping Cancer's evolution: a study to outsmart treatment resistance
Knowledge-focused Recruiting nowThis study follows 600 people with lung cancer or mesothelioma to track how their tumors evolve during and after treatment. Researchers collect blood, tissue, and imaging samples every few months to understand why some cancers come back or stop responding to therapy. The goal is …
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New study aims to make allergy testing safer for cancer patients on biologics
Knowledge-focused Recruiting nowThis study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists dive deep into mesothelioma tumors to unlock new treatment clues
Knowledge-focused Recruiting nowThis study is looking at tumor samples from 220 people with pleural or peritoneal mesothelioma, a rare cancer linked to asbestos. Researchers will analyze the genes and immune cells in these tumors to find patterns that could predict which treatments work best. The goal is to imp…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:08 UTC